provigil no prescription Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]
buy provigil uk online 9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down 3.55%, BIIB down 3.06%, ALXN down 2.66%, GILD down 2.55%, […]
go to link Update-2… 8/12 Biotech and Healthcare Holds on Emerging Market Down Day IBB down 0.55%, XBI down 0.43%, XLV down 0.43% EEM down 2.13%, QQQ down 0.76%. ==== Update-1 Rally Fades a Bit into the Close Biotech stocks were mixed trading closer to the flatline after the close on light summer volume. Macro issues such as drug […]
Updates: 7/19 pm… Abbvie (ABBV) takes a 4.7% hit on Citron short seller call. Basis for call would be pressure from FDA and Scott Gottlieb concerning stalling by drug companies on biosimilars. Many reports cite biosimilar risk to blockbuster Humira. Merck succumbs to Trump pricing pressure with a minor Hep-C drug. Mid-caps mainly green, large caps […]
Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late June. Rally is just short of hitting new 2018 highs in the sector. Biotech stocks rallied with […]
Momentous Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170 level on news that a rival Company Galapagos (GLPG) […]
Update-1 Gene Editing stocks are hit hard by a STAT Report that edited cells may cause cancer. Here is a later summary from STAT. As of 2:45 PDT trading; CRSP down 12% at $60, EDIT down 7.8% at $36.14. NTLA down 9.9% at $24.5. The report was published in Nature Medicine. After the close biotech […]
6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%. Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news. However there will be some clear cut winners after the Meeting. […]
Updates 5/30 Pre-ASCO Rally: XBI regains momentum to $94 level. IBB breaks through SMA 200 level to $108+. Many mid-caps from our watch list soaring-CRSP*, FMI, FOLD, LGND, LOXO, NKTR, SGEN, SRPT etc. *Note CRSP got whacked after hours down 13 points! The FDA has put the clinical trial for sickle cell treatment on hold. […]
Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.